Early data presented by Cassava Sciences demonstrates the safety of their Alzheimer’s drug simufilam, which is currently in Phase 3 clinical trials. But in late…
IMAGE: Photobiomodulation tabletop device Beacon40 by neurotechnology company Bright Could flickering lights have brain health benefits? Research around experimental therapies involving external stimuli —…
The human body is host to trillions of microscopic organisms — collectively called the microbiome — that shape our health across the lifespan. This…
The biotechnology company Cassava Sciences — makers of simufilam, an anti-Alzheimer’s drug currently in Phase III clinical trials — was accused of scientific misconduct…
A recent analysis reveals that people with Alzheimer’s taking Alzheimer’s drug galantamine (Razadyne), approved nearly two decades ago, show moderate cognitive benefits as well…
Scientists still don’t know why some people develop Alzheimer’s and others don’t. But while we may not fully understand the causes of Alzheimer’s, researchers…
Cassava Sciences revealed positive clinical data from their simufilam trial, a potentially disease-modifying therapy for treating Alzheimer’s. Their preliminary study showed that simufilam significantly…
UPDATE: 3 March 2024, 8:40 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…